Arkolith/Insider Trading/FDMT/Form 4

Kirn David

Chief Executive Officer, Director4D Molecular Therapeutics, Inc. (FDMT) · full profile →Form 4 · filed Jun 26, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$299K
Net Open-Market Flow
-$299K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 24, 2024Sell(S)13K$23.10$299K1.1M
Jun 24, 2024Option exercise(M)13K$14.42$186K1.1M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 24, 2024Option exercise(M)13K—$0577K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-077944) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML